EA201890801A1 - Способ лечения злокачественной рабдоидной опухоли яичников (mrto)/мелкоклеточного рака яичников гиперкальцемического типа (sccoht) с помощью ингибитора ezh2 - Google Patents

Способ лечения злокачественной рабдоидной опухоли яичников (mrto)/мелкоклеточного рака яичников гиперкальцемического типа (sccoht) с помощью ингибитора ezh2

Info

Publication number
EA201890801A1
EA201890801A1 EA201890801A EA201890801A EA201890801A1 EA 201890801 A1 EA201890801 A1 EA 201890801A1 EA 201890801 A EA201890801 A EA 201890801A EA 201890801 A EA201890801 A EA 201890801A EA 201890801 A1 EA201890801 A1 EA 201890801A1
Authority
EA
Eurasian Patent Office
Prior art keywords
sccoht
malignant
mrto
ovaries
micro
Prior art date
Application number
EA201890801A
Other languages
English (en)
Inventor
Хайке Кайльхак
Original Assignee
Эпизайм, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эпизайм, Инк. filed Critical Эпизайм, Инк.
Publication of EA201890801A1 publication Critical patent/EA201890801A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere

Abstract

В настоящем изобретении предусмотрен способ лечения злокачественной рабдоидной опухоли у субъекта, нуждающегося в этом, включающий введение субъекту терапевтически эффективного количества ингибитора энхансера гомолога zeste 2 (EZH2). В определенных вариантах осуществления этого способа злокачественная рабдоидная опухоль представляет собой мелкоклеточный рак яичников гиперкальцемического типа (SCCOHT) и ингибитор EZH2 представляет собой таземетостат (также известный как Tazemetostat).
EA201890801A 2015-09-25 2016-09-26 Способ лечения злокачественной рабдоидной опухоли яичников (mrto)/мелкоклеточного рака яичников гиперкальцемического типа (sccoht) с помощью ингибитора ezh2 EA201890801A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562233146P 2015-09-25 2015-09-25
US201562252188P 2015-11-06 2015-11-06
PCT/US2016/053673 WO2017053930A2 (en) 2015-09-25 2016-09-26 Method of treating malignant rhabdoid tumor of the ovary (mrto)/small cell cancer of the ovary of the hypercalcemic type (sccoht) with an ezh2 inhibitor

Publications (1)

Publication Number Publication Date
EA201890801A1 true EA201890801A1 (ru) 2018-09-28

Family

ID=58387531

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201890801A EA201890801A1 (ru) 2015-09-25 2016-09-26 Способ лечения злокачественной рабдоидной опухоли яичников (mrto)/мелкоклеточного рака яичников гиперкальцемического типа (sccoht) с помощью ингибитора ezh2

Country Status (12)

Country Link
US (3) US20180296563A1 (ru)
EP (1) EP3352761A4 (ru)
JP (1) JP7013369B2 (ru)
KR (1) KR20180054793A (ru)
CN (2) CN108349958B (ru)
AU (2) AU2016325643B2 (ru)
CA (1) CA2999898A1 (ru)
EA (1) EA201890801A1 (ru)
IL (2) IL258302A (ru)
MX (2) MX2018003663A (ru)
SG (1) SG10201908323TA (ru)
WO (1) WO2017053930A2 (ru)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10493076B2 (en) 2015-08-24 2019-12-03 Epizyme, Inc. Method for treating cancer
KR20180054793A (ko) * 2015-09-25 2018-05-24 에피자임, 인코포레이티드 악성 간상소체 종양 또는 고칼슘혈증형 난소의 소세포 암을 치료하는 방법
CA3011186A1 (en) 2016-01-29 2017-08-03 Epizyme, Inc. Combination therapy for treating cancer
EP3464643A4 (en) 2016-06-01 2020-04-01 Epizyme Inc USE OF EZH2 INHIBITORS FOR THE TREATMENT OF CANCER
US20200129519A1 (en) * 2016-06-08 2020-04-30 Genentech, Inc. Diagnostic and therapeutic methods for cancer
US11147819B2 (en) 2016-06-17 2021-10-19 Epizyme, Inc. EZH2 inhibitors for treating cancer
JP7324144B2 (ja) * 2017-02-02 2023-08-09 エピザイム，インコーポレイティド 癌処置様式
US11642346B2 (en) 2017-03-31 2023-05-09 Epizyme, Inc. Combination therapy for treating cancer
JP2020522687A (ja) 2017-06-02 2020-07-30 エピザイム，インコーポレイティド 癌を処置するためのｅｚｈ２阻害剤の使用
CN111093660A (zh) 2017-09-05 2020-05-01 Epizyme股份有限公司 用于治疗癌症的组合疗法
AU2020248422A1 (en) * 2019-03-26 2021-11-11 Translational Drug Development, Llc Method of treating malignant rhabdoid tumor of the ovary and small cell cancer of the ovary of the hypercalcemic type
CN110950834A (zh) * 2019-11-26 2020-04-03 济南大学 新型eed-ezh2相互作用小分子抑制剂的确定和评价
CN110960525A (zh) * 2019-11-26 2020-04-07 济南大学 新型eed-ezh2相互作用抑制剂的确定和评价

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102061353B1 (ko) * 2010-09-10 2020-01-02 에피자임, 인코포레이티드 인간 ｅｚｈ2의 억제제 및 이의 사용 방법
CN103619337A (zh) * 2011-05-16 2014-03-05 乌尔里克·努伯 新型癌症疗法和方法
EP2825161B1 (en) * 2012-03-12 2019-01-02 Epizyme, Inc. Inhibitors of human ezh2, and methods of use thereof
CN104768555B (zh) * 2012-04-13 2018-10-30 Epizyme股份有限公司 用于治疗癌症的联合治疗
RU2018145311A (ru) * 2012-10-15 2019-02-18 Эпизайм, Инк. Способы лечения рака
US20140120083A1 (en) * 2012-11-01 2014-05-01 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators
WO2015103431A1 (en) * 2013-12-31 2015-07-09 Memorial Sloan-Kettering Cancer Center Compositions and methods for the diagnosis and treatment of ovarian cancers that are associated with reduced smarca4 gene expression or protein function
EP4066834A1 (en) * 2014-03-19 2022-10-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
US10493076B2 (en) * 2015-08-24 2019-12-03 Epizyme, Inc. Method for treating cancer
KR20180054793A (ko) * 2015-09-25 2018-05-24 에피자임, 인코포레이티드 악성 간상소체 종양 또는 고칼슘혈증형 난소의 소세포 암을 치료하는 방법

Also Published As

Publication number Publication date
US20200138825A1 (en) 2020-05-07
JP2018529698A (ja) 2018-10-11
AU2016325643B2 (en) 2022-07-21
CN108349958A (zh) 2018-07-31
JP7013369B2 (ja) 2022-02-15
IL280760A (en) 2021-04-29
US20210121470A1 (en) 2021-04-29
CN114533880A (zh) 2022-05-27
EP3352761A4 (en) 2019-04-24
CN108349958B (zh) 2022-02-15
AU2022256115A1 (en) 2022-11-17
CN114533880B (zh) 2023-08-22
MX2022013390A (es) 2023-01-04
US20180296563A1 (en) 2018-10-18
MX2018003663A (es) 2018-08-14
WO2017053930A2 (en) 2017-03-30
WO2017053930A3 (en) 2018-04-12
CA2999898A1 (en) 2017-03-30
SG10201908323TA (en) 2019-10-30
AU2016325643A1 (en) 2018-04-12
KR20180054793A (ko) 2018-05-24
EP3352761A2 (en) 2018-08-01
IL258302A (en) 2018-05-31

Similar Documents

Publication Publication Date Title
EA201890801A1 (ru) Способ лечения злокачественной рабдоидной опухоли яичников (mrto)/мелкоклеточного рака яичников гиперкальцемического типа (sccoht) с помощью ингибитора ezh2
EA202092590A1 (ru) Пиридазиноны в качестве ингибиторов parp7
MX2021003389A (es) Metodos para tratar el cancer.
MX2019002303A (es) Inhibidores de procesos metabolicos celulares.
EA201992220A1 (ru) Комбинированная терапия для лечения или предупреждения опухолей
PH12016502179A1 (en) Inhibitors of lysine specific demethylase-1
EA201890730A1 (ru) Производные пиразолопиримидина в качестве ингибиторов btk для лечения злокачественного новообразования
EA201592068A1 (ru) Ингибиторы энхансера zeste гомолога 2
EA201691725A1 (ru) Соединения для лечения опосредованных комплементом нарушений
MX2017002824A (es) Inhibidores demetilasa-1 especifica de lisina.
MX2017000179A (es) Inhibidores de demetilasa-1 especifica de lisina.
EA201991214A1 (ru) Антитела против pd-1 и их композиции
MX2020010900A (es) Inhibidores de demetilasa-1 especifica de lisina.
MX2018006674A (es) Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control.
MX2021014286A (es) Proteinas multiespecificas.
MX2017000170A (es) Inhibidores de demetilasa-1 especifica de lisina.
EA201890878A1 (ru) Способ лечения медуллобластомы с помощью ингибитора ezh2
EA201791736A1 (ru) Комбинированная терапия для лечения рака
EA202192122A1 (ru) Соединения, обладающие активностью индуцирования ферроптоза, и способы их применения
MX2020012291A (es) Compuestos para el tratamiento de cancer de mama triple negativo y cancer de ovario.
EA201992137A1 (ru) ПИРИМИДОПИРИМИДИНОНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ КИНАЗЫ Wee-1
EA201792580A1 (ru) Ингибиторы ido
EA201792287A1 (ru) Способы лечения рака
EA201890868A1 (ru) Бактерии с ослабленной вирулентностью для лечения злокачественных солидных опухолей
EA201792288A1 (ru) Способы лечения рака